Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Inclusion Criteria: * A diagnosis of Secondary Progressive Multiple Sclerosis * Aged 18 to 57 years old, at the time of informed consent Exclusion Criteria: * History of clinically important (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, immune, psychiatric, hepatic, renal or hematologic insufficiency or any other major disease other than MS ( Multiple Sclerosis) * Inability in the opinion of the Investigator to comply with study requirements * Other protocol-defined criteria may apply